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Penetration of PLGA Nanoparticles into the Intracranial Rat C6Glioma:
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Introduction

Results

Our previous results have shown that PLGA
nanoparticles (PLGA NPs) coated with poloxamer 188
(P188) enable the delivery of drugs across the blood–
brain barrier (BBB) after intravenous injection.
Doxorubicin loaded PLGA NPs (Dox-PLGA) coated
with P188 produced a considerable anti-tumour effect
against the intracranial glioblastoma in rats [1]. The
objective of the present study was to evaluate the
internalization of the P188-coated PLGA NP in the
intracranial C6 glioma in rats.
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Quantitative fluorescence analysis (SLCM) on rat brain
sections with C6 glioma 2 h after i.v. administration of DiIPLGA NPs. А-B. Panoramic images - DiI-PLGA/P188 NP (А)
and uncoated NP (B). Bar=1000 μm. C-D. 3-D fluorescence
intensity histograms of the same sections.

Brain fluorescence (Ivis Spectrum CT) in rats
with glioma C6 after transcardial perfusion.
А. DiI-PLGA/P188 NP; B. Uncoated DiI-PLGA NP.
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For visualization using scanning laser confocal
microscopy (SLCM) (Nikon A1 MP) and the intravital
fluorescence imaging system IvisSpectrum CT
(Perkin-Elmer) the NP were labeled with DiI (DiI-PLGA
NP).
Preparation of drug-loaded PLGA nanoparticles.
The DiI-PLGA NP were prepared by an emulsionsolvent evaporation technique. The DiI:PLGA ratio was
1:750. The solution of PLGA and DiI in
dichloromethane was added to 1% aqueous solution of
PVA (9-10 kDa) and passed through a high-pressure
homogenizer (Panda Plus2000) at 1000 bar. The
organic solvent was evaporated under vacuum
followed by addition of 2.5% mannitol and
lyophilization. Free DiI was removed from the
nanosuspension by gel filtration chromatography using
a Sephadex G-25 column.
Nanoparticle characterization.
The average particle size and zeta-potential were
measured using a Zetasizer Nano ZS (Malvern, GB)
and were found to be 42,8 ± 2,2 nm and -11,4 ± 0,4
mV respectively.
Nanoparticle administration.
The freeze-dried NP were resuspended either in P188
or in water for injections, incubated for 30 min and
administered i.v. into rats with intracranial C6 glioma on
day 15 after tumour inoculation. The presence of mass
lesion was verified by previous MRI. Two hours after
administration of the NP, the rats were perfused
transcardially with 4% p-formaldehyde solution, organs
were recovered, and the fluorescence intensity was
assessed using an Ivis Spectrum CT system.
Histological analysis.
Brains were removed and fixed with 4% paraform
solution for at least 24h, afterwards 50 micron-thick
sections were prepared using vibrotome. To assess NP
localization in brain sections immunohistochemical
staining with antibodies against GFAP (astroglial
marker), beta-III Tubulin (neuronal marker), was
performed. Goat anti-mouse Alexa Fluor 633 and Goat
anti-rabbit Alexa Fluor 488 (Invitrogen) were used as
the second antibodies.

Rat brain sections 2 h post intravenous injection of
fluorescently labeled DiI-PLGA NP

Accumulation of DiI-PLGA/P188 NP in some
populations of neurons of contralateral
hemispere. А. Merged image. B. Fluorescence of
cell nuclei (Hoechst staining). C.Beta-III-tubulin
positive neurons of the cerebral cortex. D. DiI
fluorescence . Bar scale 50 μm. SLCM.

Accumulation of DiI-PLGA/P188 NP in Purkinje cells, 2 hours
after i.v. administration. А. Overview of the cerebellar cortex.
Bar scale 100 μm. B. Magnified fragment of cerebellar cortex, bar
scale – 50 μm. I Merged image. II.Fluorescence of cell nuclei
(Hoechst staining). III.DiI fluorescence. SLCM.
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The fluorescence intensity of the hemisphere with the implanted glioma was 4-fold higher for the P188coated NP (DiI-PLGA/P188 NP), as compared to the uncoated NP (45.1×106 vs 9.5×106 photons/sec/cm2,
respectively according to intravital fluorescence imaging data.
The quantitative fluorescence analysis of the tumor sections using SLCM showed a significantly higher
accumulation of the DiI-PLGA/P188 NP, as compared to the uncoated DiI-PLGA NP. Mean fluorescence intensity
values in the tumor were 1698.9±536.6 and 558.9±181.0 CU for the P188-coated and uncoated NP, respectively.
The intensity values in the contralateral hemispheres for the same preparations were 293.4 ± 32.3 and 203.2 ±
22.9 CU, respectively. Thus, according to the SLCM data, the penetration of the DiI-PLGA/P188 NP into the tumor
was 3 times more effective than that of the uncoated NP. The analysis of the magnified fluorescence images
showed considerable accumulation of the DiI-PLGA/P188 NP both in the tumor interstitial fluid and inside the C6
glioma cells. At the same time, DiI-PLGA-NPs were mainly localized in epithelial cells of cerebral microvessels of
the contralateral hemisphere. Relatively intense DiI fluorescence was also observed in Purkinje cells of cerebellar
cortex.
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Together with the data obtained previously, the results of the present study demonstrate that coating of the
PLGA NP with poloxamer 188 considerably enhances NP delivery to the brain tumor.
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